Table 1.
Patient characteristics.
| Baseline characteristics | All patients evaluable (N = 15) | First-line consolidation (N = 11) | Relapsed group (N = 4) | P |
|---|---|---|---|---|
| Median age, years (range) | 51 (23–70) | 45 (23–70) | 54.5 (31–61) | 0.447 |
| Age ≥ 35 years, n (%) | 10(66.7%) | 7(63.6%) | 3(75%) | 0.68 |
| Male, n (%) | 6 (40%) | 5 (45.5%) | 1 (25%) | 0.348 |
| ECOG performance status score of 0–1, n (%) | 15 (100%) | 11 (100%) | 4 (100%) | >0.99 |
| Median time since diagnosis, months (range) | 6.5 (1–41.5) | 6.5 (3–18) | 7 (1–41.5) | 0.851 |
| Median Cycle Number of chemotherapy, n (range) | 4(3–8) | 4(3–5) | 3.5 (3–8) | 0.949 |
| Ph-positive | 7(46.7%) | 3(27.3%) | 4(100%) | 0.026 |
| Disease burden | ||||
| Before lymphodepletion | ||||
| MRD ≥ 10–2 | 2(13.3%) | 1(9.1%) | 1(25%) | 0.4 |
| MRD ≥ 10–3–<10–2 | 5(33.3%) | 3(27.3%) | 2(50%) | |
| MRD ≥ 10–4–<10–3 | 8(53.3%) | 7(63.6%) | 1(25%) | |
| Before infusion | ||||
| MRD ≥ 10–2 | 3(21.4%) | 1(9.1%) | 2(50%) | 0.183 |
| MRD ≥ 10–3–<10–2 | 5(35.7%) | 5(45.5%) | 0 | |
| MRD ≥ 10–4–<10–3 | 1(7.1%) | 1(9.1%) | 0 | |
| MRD Negative | 5(35.7%) | 3(27.3%) | 2(50%) | |
| Follow-up time | 15.5(2.5–33) | 15.5(2.5–33) | 15.25(10.5–20.5) | 0.949 |